Temporal changes in the GII.4 human norovirus capsid sequences occasionally result 23 in the emergence of genetic variants capable of causing new epidemics. The GII.4 24 persistence is believed to be associated with the recognition of numerous histo-blood 25 group antigen (HBGA) types and antigenic drift. We found that one of the earliest 26 known GII.4 isolate (1974) and a more recent epidemic GII.4 variant (2012) had 27 varied norovirus-specific monoclonal antibody (MAb) reactivities, yet similar HBGA 28 binding profiles. To better understand the binding interaction of one MAb (10E9) that 29 had varied reactivities with these GII.4 variants, we determined the X-ray crystal 30 structure of the NSW-2012 GII.4 P domain 10E9 Fab complex. We showed that the 31 10E9 Fab interacted with conserved and variable residues, which could be associated 32 with antigenic drift. Interestingly, the 10E9 Fab binding pocket partially overlapped 33 the HBGA pocket and had direct competition for conserved HBGA binding residues 34 (i.e., Arg345 and Tyr444). Indeed, the 10E9 MAb blocked norovirus VLPs from 35 binding to several sources of HBGAs. Moreover, the 10E9 antibody completely 36 abolished virus replication in the human norovirus intestinal enteroid cell culture 37 system. Our new findings provide first direct evidence that competition for GII.4 38 HBGA binding residues and steric obstruction could lead to norovirus neutralization. 39
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On the other hand, the 10E9 MAb recognized residues flanking the HBGA pocket, 40 which are often substituted as the virus evolves. This mechanism of antigenic drift 41 likely influences herd immunity and impedes the possibility of acquiring broadly 42 reactive HBGA-blocking antibodies. 43 IMPORTANCE 44
45
The emergence of new epidemic GII.4 variants is thought to be associated with 46 changes in antigenicity and HBGA binding capacity. Here, we show that HBGA 47 binding profiles remain unchanged between 1974 and 2012 GII.4 variants, whereas 48 these variants showed varying levels of reactivities against a panel of GII.4 MAbs. 49
We identified a MAb that bound at the HBGA pocket and blocked norovirus VLPs 50 from binding to HBGAs and neutralized norovirus virions in the cell culture system. 51
Raised against GII.4 2006 strain this MAb was unreactive to GII.4 1987 isolate, but 52 was able to neutralize newer 2012 strain, which has important implications for 53 vaccine design. Altogether, these new findings suggested that the amino acid 54 variations surrounding HBGA pocket lead to temporal changes in antigenicity without 55 affecting the ability of GII.4 variants to bind HBGAs, which are known co-factors for 56 infection. 57
INTRODUCTION 58 59
Human noroviruses are a major cause of outbreaks of acute gastroenteritis worldwide. 60
The human norovirus genome contains three open reading frames (ORFs), where 61 ORF1 encodes non-structural proteins, ORF2 encodes capsid protein, and ORF3 62 encodes a minor capsid protein (1). Human noroviruses are grouped into several 63 genogroups (i.e., GI, GII, and GIV), which are subsequently sub-grouped into 64 numerous genotypes. Norovirus capsid genes frequently evolve into genetically and 65 antigenically variants, which have sometimes resulted in epidemics and even 66 pandemics (2). The GII genotype 4 (GII.4) variants have dominated over the past two 67 decades and have approximately 5% capsid amino acid divergence from previous 68 epidemic GII.4 variants. The capsid of each variant likely accumulates advantageous 69 mutations from the preceding variant. Antigenic drift has therefore been proposed as a 70 major driving force in the emergence of novel GII.4 variants (3, 4) . 71
72
Expression of the human norovirus ORF2 in insect cells results in the formation of 73 virus-like particles (VLPs) that are antigenically and morphologically similar to 74 native virions. The X-ray crystal structure of norovirus VLPs from the prototype 75 strain (GI.1) identified two domains, termed shell (S) and protruding (P) domains (5). 76
The S domain surrounds the viral RNA, whereas the P domain, which can be further 77 subdivided into P1 and P2 subdomains, contains determinants for cell attachment and 78 antigenicity. 79
80
Human noroviruses bind to histo-blood group antigens (HBGAs) and this interaction 81 is important for infection (6) (7) (8) (9) (10) (11) . The X-ray crystal structures of the P domains from 82 epidemic GII.4 variants in complex with a panel of HBGA showed that a regular set 83 of conserved residues (i.e., Asp374, Arg345, Thr344, Tyr444, and Gly443) usually 84 holds both the ABH-and Lewis-fucose of HBGAs (12) (13) (14) (15) . Interestingly, the HBGA 85 binding profiles of the antigenically distinct GII.4 variants have likely remained 86 unchanged over the past decades (13, 16) . Indeed, the region immediately beneath the 87 HBGA binding pocket showed little variation, whereas the surrounding residues 88 displayed moderate amino acid substitutions (13) . 89 90 Immunity to norovirus is still poorly understood (17), although volunteer studies have 91
shown that protective immunity after infection may be absent or short-lived (18). 92
Indeed, infection might not confer immunity against another genotypes or even 93 variants within a genotype (19) (20) (21) . Therefore, antigenic changes and HBGA binding 94 capacities are likely an important driving force behind the GII.4 continued persistence 95 and repeated occurrence in world-wide epidemics (19, 21) . 96
97
A number of studies have discovered norovirus specific antibodies that can block 98 HBGA binding and higher levels of antibodies that blocked VLP binding to HBGAs 99 were associated with a lower risk of disease (22) (23) (24) (25) (26) . Recently, an IgA MAb isolated 100 from a volunteer infected with GI.1 norovirus was shown to have HBGA blocking 101 activity and bound to surface-exposed loops in the vicinity of HBGA binding site 102 (23). However, the ability of this antibody to neutralize native virus has not been 103 determined. Moreover, the IgA was GI.1 specific and lacked blocking activity against 104 other GI genotypes. Likewise, we discovered a Nanobody (VHH) that bound at the 105 GII.10 HBGA pocket and showed convincing HBGA blocking potential, but was also 106 genotype specific (27) . Other Nanobodies were shown to inhibit norovirus binding to 107
HBGAs by several distinct mechanisms, including allosteric inhibition and disruption 108 of capsid integrity (27) . 109 Recently, a system utilizing human intestinal enteroids (HIE) was reported to support 111 replication of human norovirus (10). Moderate replication levels could be enhanced 112 with addition of bile acids, however the replication success was still strongly 113 dependent on the particular stool sample (28). This cell culture system highlighted the 114 requirement of HBGAs on the surface of permissive cells and showed that HBGA 115 blocking sera can effectively neutralize norovirus. Importantly, the HIE system was 116 used to evaluate the neutralizing properties of 25 different GII.4 specific IgG and IgA 117 isolated from a human donor (28). Several antibodies were able to neutralize human 118 norovirus and were predicted to bind to the P domain, however the precise binding 119 sites were not yet determined. Likewise, the mechanism of the neutralization and 120
HBGA binding inhibition was not defined. 121
122
In this study, we examined antigenic drift with one of the earliest known GII.4 isolate 123 (CHDC-1974) and two recent epidemic GII.4 variants (Saga-2006 and UNSW-2012) . 124
We found that GII.4 variants showed mixed MAb reactivities, while retaining HBGA 125 binding. Following this result, we determined the X-ray crystal structure of a GII.4 126 variant-specific MAb (termed 10E9) in complex with the GII.4 P domain. 127
Interestingly, the 10E9 MAb partially overlapped the HBGA pocket and this 128 interaction blocked VLPs from binding to surrogate sources of HBGAs and 129 neutralized norovirus in the HIE system. Overall, these data suggested that antibodies 130 that compete with the GII.4 HBGA binding site could effectively neutralize norovirus, 131 but antigenic drift likely limits broad antibody inhibition. 132
133

MATERIALS AND METHODS 134
VLP production 135
The CHDC-1974 (ACT76142), Saga-2006 (AB447457) , and NSW-2012 (JX459908) 136 VLPs were expressed as described (29). The VLPs were purified using CsCl 137 equilibrium gradient ultracentrifugation at 35000 rpm for 24 h at 4C (Beckman 138 SW55 rotor). The integrity of the VLPs was confirmed by negative-stain electron 139 microscopy (EM). VLPs were diluted in water, applied on carbon coated EM grids 140 and stained with 1% uranyl acetate. The grids were examined on a Zeiss 910 electron 141 microscope (Zeiss, Oberhofen, Germany) at 50,000-fold magnification. 142 143
MAb reactivities 144
Eleven different IgG MAbs (Virostat, USA) were purified from a mouse immunized 145 using the GII.4 Minerva-2006 VLPs (Genbank accession number AFJ04709.1). The 146
Minerva capsid sequence had 99%, 95%, and 90% amino acid identity with Saga-147 2006 , NSW-2012 , and CHDC-1974 . The antibody titers were quantified 148 using a direct ELISA (30). Briefly, microtiter plates were coated with 5 μg/ml of 149 GII.4 VLPs. The VLPs were detected with serially diluted MAbs and then a 150 secondary HRP-conjugated goat anti-mouse MAb (Sigma, Germany). Absorbance 151 was measured at 490 nm (OD 490 ) and the binding cut-off was set to OD 490 = 0.15 as 152 previously determined (31). All experiments were performed in triplicate. 153
154
HBGA binding assay 155
The binding of CHDC-1974 and NSW-2012 VLPs to porcine gastric mucin type III 156 (PGM; containing HBGAs), saliva (A-and B-types), and synthetic HBGAs (A-and 157 B-types) were measured using ELISA assays (32) (33) (34) (35) . For the PGM assay, 96-well 158 plates were coated with 10 μg/ml of PGM for 4 h at room temperature (RT). For 159 saliva assay, the saliva was first heated at 95°C for 10 min, briefly centrifuged, and 160 then the supernatant was diluted 1:500 in PBS and added to wells overnight at 4°C. 161
The PGM and saliva plates were washed three times with PBS containing 0.1% 162 Tween20 (PBS-T), and blocked with 5% skim milk (SM) in PBS overnight at 4°C. 163
The VLPs were two-fold serially diluted in PBS, added to duplicate wells, and then 164 incubated for 1 h at 37°C. Plates were washed as before and reacted with HRP-165 conjugated goat α-mouse for 1 h at 37°C. Plates were washed and then developed 166
with o-phenylenediamine and H 2 O 2 in the dark for 30 min at RT. The reaction was 167 stopped with 3 N HCl and absorbance was measured at 490 nm (OD 490 ). For the 168 synthetic HBGA binding assay, ELISA plates were coated with 15 μg/ml VLPs 169 overnight at 4°C, washed with PBS-T and blocked with 5% SM. Synthetic HBGA 170 conjugated with PAA-biotin (A-trisaccharide and B-trisaccharide; Glycotech) were 171 two-fold serial diluted and added to duplicate wells for 2 h at 37°C. Plates were then 172 incubated with streptavidin-HRP for 1 h at 37°C. Plates were developed as described 173 above. All experiments were performed in triplicate. 174
175
10E9 Fab preparation 176
The 10E9 Fab (Fab #7 in this study) was prepared as described in a previous 177 publication (29). Briefly, approximately 50 mg of purified 10E9 IgG was used for Fab 178 preparation. The IgG was first reduced in 100 mM DTT (pH 7.6) for 1 h at 37C. The 179
reduced IgG was dialyzed in gel filtration buffer (GFB: 0.35 M NaCl and 2.5 mM 180 Tris pH 7.4) supplemented with 20 mM HEPES (pH 7.7) for 1 h at 4C. The IgG was 181 alkylated in GFB supplemented with 2 mM iodoacetamide for 48 h at 4C, and then 182 transferred to GFB supplemented with 20 mM HEPES for 1 h at 4C. The IgG was 183 concentrated to 6 mg/ml and then digested with ficin using a commercial kit (Pierce, 184
Rockford, USA). The Fab was separated from the Fc in a Protein A column and the 185 resulting Fab was further purified by size exclusion chromatography with a Superdex 186 200 column (GE) and concentrated to 5 mg/ml and stored in GFB. The Fab sequence 187 was determined using a commercial service (ImmunoPricise Antibodies, Canada). 188 189
Crystallization of NSW-2012 P domain Fab complex 190
The NSW-2012 P domain was expressed in E. coli and purified as described (30, 35, 191 36) . The NSW-2012 P domain and 10E9 Fab were mixed in a 1:1.4 molar ratio and 192 the complex purified using size exclusion chromatography. Crystals were grown in a The biologically relevant Fab-binding interface was determined using an online server 208 (PDBePISA) and had a large surface area between the P domain and both Fab chains 209 (heavy chain, ~550 Å 2 and light chain, ~354 Å 2 ). Alternative binding interfaces were 210 located outside the CDRs and/ or had small area of interaction (<250 Å 2 ). Atomic 211 coordinates and structure factors are deposited in the Protein Databank (6EWB). 212
213
10E9 Fab blocking assay 214
Blocking assays were performed as descried earlier (34) experiments were performed with titrating the P domain into PBS. The heat 230 associated with the control titrations was subtracted from the raw binding data prior to 231 fitting. The data was fitted using a single set-binding model in Origin 7.0 (OriginLab, 232
Northampton, MA). Binding sites were assumed to be identical. conditioned media were produced as was reported previously (10). Wnt3 activity was 240 tested using TCF reporter plasmid kit (Merck). Complete growth media (CMGF+), 241 basal media (CMGF-) and differentiation media were all prepared as described in 242 (10). HIE were grown as 3D cultures in Matrigel in CMGF+ as previously described 243 (10). For infection experiments, HIE were trypsinized and grown as 2D monolayers in 244 a collagen coated 96 well plates as previously reported (10). After one day the 245 CMGF+ media was changed to differentiation media for five days. Monolayers were 246 pretreated with 500 μM GCDCA for two days before infection experiments. 247
248
HIE infection and inhibition 249
Confluent monolayers were washed once with ice cold CMGF-and incubated at 37°C 250 for 1 h with diluted stool samples. Stool samples were kindly provided by M. Estes, 251 H. Schroten (Mannheim Children Hospital, Mannheim, Germany), and P. Schnitzler, 252 (Heidelberg University Clinic, Heidelberg, Germany). After infection monolayers 253
were washed twice with ice cold PBS, and incubated in differentiation media 254 supplemented with 500 μM GCDCA or 500 μM GCDCA and 1% human bile. 255
Samples were frozen at 0 days post infection (dpi), i.e., 1 h after virus attachment and 256 4 dpi. For inhibition experiments 10E9 MAb was diluted in PBS to a stated 257 concentration, mixed with the virus in 1:1 ratio and incubated for 1 h at 37°C. After 258 preincubation the samples were diluted with CMGF-with 500 μM GCDCA and 259 applied on washed HIE monolayers for 1 h at 37°C. Isotype IgG (anti-myosin heavy 260 chain antibody, Abcam) was used as a negative control. Plates were washed and 261 incubated as above. All experiments were performed three times with technical 262 duplicates or triplicates. 263
264
RNA extraction and RT-qPCR 265
Viral RNA was extracted at 0 and 4 dpi using RNAeasy mini kit (Quagen) or phenol/ 266 chlorophorm extraction with Ribozol according to manufacturer instructions. Genome 267 copy levels were measured using qScript XLT One-step RT-qPCR ToughMix reagent 268 with ROX (Quanta Bioscineces) using COG2R/ QNIF2D primer pair, and probe 269 QNIFS as described previously (10, 28 
Antibody reactivities against VLPs 278
In order to analyse temporal changes in antigenicity, we examined the reactivities of 279 the CHDC-1974 , Saga-2006 , and NSW-2012 (Fig. 1A) with 11 different GII.4 280 norovirus MAbs (termed MAbs #1 to #11) that were produced in a mouse immunized 281 with the GII.4 Minerva-2006 isolate. We found that 11 MAbs reacted against the 282 Saga-2006 VLPs (Fig. 1B) 
VLP binding interactions with HBGAs 295
Our previous structural study of Farmington Hills-2004 , Saga-2006 , and NSW-2012 GII.4 variants confirmed that these noroviruses were capable of binding numerous 297 HBGA types, despite having varied residues interacting with the terminal HBGA 298 saccharides (13). To compare the HBGA binding interactions of one of the earliest 299 known GII.4 strain (CHDC-1974) with the prevalent NSW-2012 variant, we 300 performed different HBGA binding assays using the CHDC-1974 and NSW-2012 301 GII.4 VLPs (Fig. 2) . We found that both the CHDC-1974 and NSW-2012 VLPs 302 bound to pig gastric mucin (PGM) in a dose-dependent manner. The CHDC-1974 303 VLPs bound to PGM at 0.47 µg/ml, while the NSW-2012 VLPs bound at 0.31 µg/ml 304 ( Fig. 2A) Together with our previous structural data, these results suggested that these GII.4 311 variants maintained similar HBGA binding interactions. GII.4 variants revealed that most substitutions occurred in the P2 subdomain (Fig. 3) . 315
A single amino acid insertion located at position 394 distinguished the older (i.e., 316 1974 strain) and newer GII.4 sequences (i.e., 2004 and onwards). The P domain 317 residues interacting with the ABH-fucose moiety of HBGAs have for the most part 318 remained highly conserved among these GII.4 variants (Fig. 3) . 319 320
Structure of NSW-2012 P domain 10E9 Fab complex 321
The ELISA data showed that MAb #7 (also termed 10E9 MAb) was reactive against 322 10E9 Fab bound at the upper-side of the P domain (Fig. 4A) . The overall structure of 330 the P domain in the P domain-Fab complex structure was reminiscent of the unbound 331 P domain, except for some minor loop movements (chain A: residues 338-342; and 332 chain B: residues 389-399) (13). 333
334
The binding interface presented an exceptional surface complementarity and involved 335 numerous hydrogen bonds and hydrophobic interactions (Fig. 4B) . The heavy chain 336 of 10E9 Fab interacted with both P domain monomers (interface area 349Å 2 with 337 chain B and 239Å 2 with chain A), whereas the light chain was only involved in 338 monomeric interactions (interface area 543Å 2 ). Interacting residues were primarily 339 located in the heavy chain CDRH1 and CDRH3 and the light chain CDRL2 and 340 CDRL3. Fourteen P domain residues (chain A: Asp391, Thr394, Thr395, Arg397, 341
Arg435, Tyr444, Asn446, Asp448, Gln504, and Asp506; chain B: Thr340, Asp341, 342
Ser343, and Arg345) formed nineteen direct hydrogen bonds with 10E9 Fab. Two P 343 domain residues (chain A: Arg397; and chain B: Asp341) were involved in five 344 electrostatic interactions. Two hydrophobic interactions were formed between 345
Phe250, Arg397 (P domain chain A) and Tyr51, Trp90 (Fab light chain). A similar set 346 of binding interactions was observed with the second Fab molecule. 347 348 An amino acid sequence alignment showed that most (13/14) of the NSW-2012 P 349 domain-Fab binding residues were conserved in Saga-2006, whereas in the CHDC-350 1974 only 8 of 14 were shared (Fig. 3) . These results indicated that the residues 351 substituted in CHDC-1974 inhibited 10E9 MAb from binding to CHDC-1974 VLPs 352 (Fig. 1C) The X-ray crystal structure of the NSW-2012 P domain-Fab revealed that the Fab 360 bound nearby the HBGA pocket (Fig. 4) . Superposition of the NSW-2012 P domain 361 10E9 Fab complex onto the NSW-2012 and Saga-2006 P domain HBGA complex 362 structures revealed that the side-chains of the Fab residues clashed with the HBGAs 363 ( Fig. 5) . These results indicated that 10E9 MAb might block norovirus from binding 364
to HBGAs not only through a direct competition for residues in the HBGA binding 365 site (Arg345 and Tyr444), but also by steric hindrance with HBGA pocket (Figs. 5B 366 and 5C). A similar mechanism of inhibition was recently discovered with a GI.1 IgA 367
MAb isolated from a volunteer infected with human norovirus (23). Comparison of 368 these two complex structures indicated that partial MAb overlap of the GI.1 and GII.4 369 HBGA pocket could provide HBGA blocking capabilities (Fig. 5D) . 370
371
HBGA blocking properties of 10E9 Fab 372
In order to determine the HBGA blocking potential of the 10E9 MAb, we analyzed 373
Saga-2006 and NSW-2012 VLP inhibition in the well-established HBGA surrogate 374 neutralization assay (32) (33) (34) (35) . We found that the 10E9 Fab inhibited the Saga-2006 375 VLPs binding to PGM and saliva in a dose-dependent manner (Fig. 6) . The 10E9 Fab 376 IC 50 in the PGM assay = 20 μg/ml, in the A-type saliva assay the IC 50 = 7.9 μg/ml, 377 and in the B-type saliva assay the IC 50 = 6.7 μg/ml. The 10E9 Fab failed to effectively 378 block the NSW-2012 VLPs from binding to PGM and saliva, where at the highest 379 concentration only 35% inhibition was observed. Thus, although 10E9 recognized 380 both Saga-2006 and NSW-2012 at comparable levels, they were distinguished in the 381 HBGA blocking assay. The reason for this difference in inhibition was not apparent, 382
although amino acid variations surrounding the Saga-2006 and NSW-2012 HBGA 383 pockets (Fig. 3) Overall, our data indicated that the 10E9 MAb might function as GII.4 HBGA 390
inhibitor. In order to determine the thermodynamic properties of 10E9 MAb binding 391
to NSW-2012 P domain we analyzed the binding interaction using ITC (Fig. 7) . The 392 10E9 IgG binding to the P domain was characterized with exothermic type of reaction Thermodynamic data from the 10E9 IgG binding to the P domain indicated that both 396 hydrogen bonds and hydrophobic interactions were involved in binding. The 10E9 397
IgG affinity was equivalent to the GI.1 IgA Fab (K d = 20 nM) (23). Interestingly, 398
although MAbs have two antigen recognition regions per molecule, the stoichiometry 399 of 10E9 IgG binding to the P domain was ~1 (0.98). This result indicated that each 400 antibody binds one monomer of the P domain. As the P domain forms a dimer in 401 solution, it is likely that each P domain dimer bound two 10E9 MAb molecules. 402 403 10E9 MAb neutralization of GII.4 norovirus 404
The HIE system was evaluated in order to confirm the potential neutralizing 405
properties of the 10E9 MAb with two different norovirus-positive stool samples, i.e., 406 the previously validated GII.4 TCH12-580 (10) and another GII.4 stool sample with 407 low, but consistent replication levels (GII.4 Mannheim 2018) . Of note, we 408 encountered difficulties in finding a stool sample with good replication levels as all 409 ten tested samples showed limited increase in genome copies (<50 times) despite high 410 virus load. Diluted stool samples were preincubated with the 10 μg/ml of 10E9 IgG 411 before HIE infection. At this concentration, complete neutralization of the virus was 412 observed for both stool samples at 4 dpi (Figs. 8A and 8B) . In order to further analyze 413 the neutralization properties, the 10E9 MAb was serially diluted and then incubated 414 with the GII.4 TCH12-580 stool sample. We found that the 10E9 neutralized GII.4 415 TCH12-580 in a concentration dependent manner with IC 50 value of 97 ng/ml (Fig.  416   8C) . This result was different to the PGM blocking assay, which showed only ~15% 417 inhibition with the genetically related UNSW-2012 VLPs and was ~200 times lower 418 than IC 50 (20 μg/ml) in HBGA blocking assay for GII.4 Saga-2006 VLPs (Fig. 6) . 419
Interestingly, 10E9 IgG reduced the number of input virus particles compared to 420 untreated sample as seen by the reduction of genome copies at 0 dpi (Figs. 8 A and 421 8B) . This result indicated that 10E9 IgG reduced the virus attachment to the cell 422 monolayer by preventing the binding to HBGAs on the cell surface. Overall, these 423 results confirmed that 10E9 MAb inhibited norovirus replication. 424 DISCUSSION 425
426
A plethora of studies have identified norovirus specific antibodies that block 427 norovirus VLPs from binding to . However, how these antibodies 428 block the HBGA pocket is not completely understood. The mechanisms of HBGA 429 binding inhibition can include sterical hindrance, allosteric inhibition and interference 430 with capsid morphology (27, 43) . Moreover, information on antigenic drift associated 431 with the emergence on novel variants at the atomic level is lacking. In this current 432 study, we were interested in explaining GII.4 antigenic drift and deciphering how 433 amino acid substitutions might prevent antibody binding with closely related strains. 434
435
Our structural data, together with antibody binding and HBGA blocking results, 436 indicated that the 10E9 MAb was GII.4 variant specific. The excessive substitutions 437 of residues surrounding HBGA pocket could explain the lack of 10E9 MAb reactivity 438 with older GII.4 strains, as the CDR regions of the antibody were tailored for the 439 specific sequence of newer GII.4 variants. Interestingly, 10E9 Mab raised against 440 GII.4 2006 strain could recognize and neutralize newer GII.4 2012 variant. 441 Characterization of 10E9 MAb and its binding epitope is therefore especially relevant 442 for the purpose of vaccine development against constantly evolving human norovirus. 443
At the same time, the P domain residues interacting with the ABH-fucose moiety of 444
HBGAs have for the most part remained highly conserved among CHDC-1974 , 445 Farmington Hills-2004 , Saga-2006 , and NSW-2012 
variants. Consistent with 446
HBGA findings, another study of GII.4 variants also showed conserved HBGA 447 binding profiles (16) . 448
449
Antigenic changes in amino acid positions adjacent to the receptor binding site are 450 frequently observed in another rapidly evolving RNA virus, influenza virus. In a 451 striking difference to human norovirus, the temporal antigenic and genetic changes 452 have caused the remarkable shifts in specificity and affinity for sialic acid receptors in 453 pandemic influenza strains. 454
455
The mechanism of antigenic drift, while retaining HBGA binding may not be limited 456 to the norovirus GII.4 variants, since another studies with GI specific human 457 norovirus IgA antibody and GII.10 specific Nanobody displayed similar findings (23, 458 27) . The structure of GI.1 specific IgA 5I2 showed that orientation of the bound Fab 459 fragment was extraordinarily similar to that of 10E9 IgG. Both antibodies acted by 460 steric interference and bound on the side of the HBGA pocket leaving the HBGA 461 binding site still largely exposed. This mode of binding seems to be quite beneficial 462 for the virus as it allows it to maintain a constant set of HBGA binding residues while 463 modifying the surrounding region to escape antibody recognition. One hypothesis 464 could be that the virus binds soluble HBGAs at the first encounter, which can than act 465 as a shield for underlying residues, masking it from host antibody selection. Additionally, the Fab light chain was coordinated with two hydrophobic interactions 691
between Fab Tyr51 and P domain Phe250 (chain A) and between Fab Trp90 and 692 uncharged part of Arg397 on the P domain. Two electrostatic interactions were also 693 observed (Fab Trp90 and P domain chain A Arg397; Fab Lys52 and P domain chain 694 A Asp448). the Saga-2006 VLPs, the PGM assay for 10E9 Fab IC 50 value = 20 μg/ml, for the A-715 type saliva assay, the 10E9 Fab IC 50 = 7.9 μg/ml, and for the B-type saliva assay, the 716 10E9 Fab IC 50 = 6.7 μg/ml. For the NSW-2012 VLPs, the 10E9 Fab IC 50 for the PGM 717 and saliva was not calculated, since only approximately 15-35% of inhibition was 718 achieved at the highest Fab concentration. 
